Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13785308 | 0.92 | HCAR2 (0.34) | HCAR2ALDH1A1LMNAGRM1TSHR | |
| SCHEMBL13785298 | 0.90 | ALDH1A1 (0.36) | ALDH1A1LMNATSHRCHRM1HSD17B10 | |
| SCHEMBL2754861 | 0.89 | GRM1 (0.36) | HCAR2ALDH1A1LMNAGRM1TSHR | |
| SCHEMBL17617113 | 0.89 | LMNA (0.38) | HCAR2ALDH1A1LMNAGRM1TSHR | |
| SCHEMBL9870240 | 0.84 | HCAR2 (0.38) | HCAR2ALDH1A1LMNAGRM1TSHR | |
| SCHEMBL2444342 | 0.84 | ACHE (0.38) | ALDH1A1TSHRCHRM1HSD17B10CHRM2 | |
| SCHEMBL13785299 | 0.82 | THRB (0.34) | ALDH1A1LMNATSHRCHRM1HSD17B10 | |
| SCHEMBL18101008 | 0.82 | ALDH1A1 (0.33) | ALDH1A1LMNATSHRCHRM1HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28782120 | 0.82 | LMNA (0.39) | HCAR2ALDH1A1LMNAGRM1TSHR | |
| SCHEMBL11008377 | 0.82 | TSHR (0.38) | ALDH1A1TSHRCHRM1RAB9ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | API CORPORATION (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20110286935-A1 | Multi-Functional Nano-Device | ATRP Solutions, Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-0629603-B1 | Process for the production of esters | MITSUBISHI GAS CHEMICAL CO (JP) | 1997-10-29 | — | — | EP | disclosed |
| US-5463095-A | Process for the production of esters | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0629603-A1 | Process for the production of esters | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | MGMT, GSTA1, CBS | HCAR2 4403/4885ALDH1A1 236/4885LMNA 4014/4885 |
| US-20110286935-A1 | Multi-Functional Nano-Device | CD47, FCGRT, FCGR3B | HCAR2 2761/4885ALDH1A1 2541/4885LMNA 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.